Filing Flows › Capricor Therapeutics (CAPR) › Q4 2024
Capricor Therapeutics (CAPR) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 26, 2025
Capricor Therapeutics (CAPR) reported revenue of $11.1M for the fourth quarter 2024 (Q4 2024), -8% from a year earlier and +392% from the quarter before. Operating margin was -69.1%, net loss $7.1M (63.9% of revenue).
Capricor Therapeutics, Q4 2024: revenue $11.1M (-8% year over year), operating margin -69.1%, net loss $7.1M, operating cash flow −$14.8M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $11.1M | +392% | -8% |
| Operating profit | −$7.7M | — | — |
| Net earnings | −$7.1M | — | — |
| Operating cash flow | −$14.8M | — | — |
What changed
Revenue was $11.1M in Q4 2024, down 8% year over year and up 392% from the previous quarter.
Operating costs exceeded revenue by $7.7M, an operating margin of -69.1%. Total costs grew 41% against a revenue fall of 8%. The fastest-growing cost line was Research & development (+46%). The quarter ended with a net loss of $7.1M, narrower than the previous quarter's $12.6M loss.
Operating cash flow was −$14.8M. Non-cash charges added back $376K of depreciation and $2.3M of share-based compensation. Working capital and other items used $10.4M. Capital expenditures of $489K exceeded it, leaving free cash flow of −$15.3M.
Questions
What was Capricor Therapeutics' revenue in the fourth quarter 2024?
Capricor Therapeutics (CAPR) reported revenue of $11.1M for the fourth quarter 2024 (Q4 2024), -8% from a year earlier and +392% from the quarter before.
Was Capricor Therapeutics profitable in the fourth quarter 2024?
Operating loss was $7.7M (-69.1% of revenue) and net loss $7.1M.